Alnylam Authorizes $1.0 Billion Share Repurchase; CCO Tanguler to Depart
Alnylam Pharmaceuticals’ board authorized a program to repurchase up to $1.0 billion of common stock, according to an 8-K filed Thursday. Repurchases may run in the open market, including under Rule 10b5-1 plans, in privately negotiated deals, or by other means consistent with Rule 10b-18 and other securities laws.
In the same filing, the company said Executive Vice President and Chief Commercialization Officer Tolga Tanguler will leave in December 2026. Alnylam and Tanguler intend to put the exit terms in a written agreement by his separation date.
A billion-dollar authorization is a capital-return signal alongside Alnylam’s commercial RNAi franchise. The filing does not set a deadline for completing the program or state how much will be executed in any period, so the actual pace will show up in future 10-Q and 10-K repurchase tables.
Pairing a large buyback with a commercialization-leadership change puts attention on whether product execution stays on plan while a new commercial lead is named.
Why it matters
Buyback authorizations reshape per-share math and cash priorities for biotech investors who often prefer pipeline reinvestment. The $1.0 billion ceiling is large enough to matter for float and EPS optics if management uses it.
By the numbers
- Repurchase authorization: up to $1.0 billion
- Authorization date: Nov. 2, 2026
- Tanguler planned departure: December 2026
- Role: EVP, Chief Commercialization Officer
Sources
- Alnylam Pharmaceuticals, Inc. Form 8-K Items 5.02/8.01, filed Nov. 5, 2026 (accession 0001178670-26-000080)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.